Experimental Study of Nanostructured Lipid Carrier in the Treatment of Immune Lupus Nephritis.

Lupus nephritis (LN) is a common, frequently-occurring and refractory renal medical disease. With the progress of society, the improvement of people's living standards, changes in lifestyles, and drug abuse, the incidence rate is increasing year by year. The effect of treatment on it is currently unsatisfactory clinically, and the recurrence rate is relatively high, which seriously affects People's quality of life. Therefore, the disease has become a hot and difficult point of research. In recent years, the pathogenesis and treatment of this disease have been thoroughly studied at home and abroad, especially the application of hormones and cyclophosphamide, which have achieved relatively good clinical effects. In this paper, nanostructured lipid carriers were prepared and their pharmacodynamics were studied in the treatment of mice with immunological lupus nephritis. The main experimental methods and results show that the nanostructured lipid carrier TWHF-NLC prepared by the high-pressure microjet method is characterized by transmission electron microscopy, and the TP-NLC has a uniform particle size, and the nanoparticles are spherical or short rod-shaped. Animal experiments show that TWHF-NLC has obvious therapeutic effect on mice with immune lupus nephritis. Pathological sections of the kidney showed that TWHF-NLC can effectively reduce the collagen content of the renal interstitial cells, and remove MCP-1 deposited in the kidney, and inhibit its expression.